Navigation Links
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Date:10/17/2007

Plans to Move Forward with Phase III

MALVERN, Pa., Oct. 17 /PRNewswire/ -- Cutanea Life Sciences, an emerging specialty pharmaceutical company focused on improving human health and appearance through the development and commercialization of treatments for diseased and aging skin conditions, today announced results from its completed Phase II clinical trial of Omiganan.

The trial compared Omiganan 2.5% and 1% topical gel to vehicle in subjects with papulopustular rosacea. Study results demonstrated that the formulation was safe and well-tolerated at all doses tested. Among the once-daily treatment arms, a dose-dependent response was observed in both lesion reductions and Treatment Success, as defined by Investigator Global Assessment (IGA) scores. After nine weeks of treatment, once-daily (QD) Omiganan 2.5% gel showed superior lesion count reductions and Treatment Success, compared to 1% Omiganan QD and vehicle. Omiganan provided greater improvements compared to vehicle among patients with a more severe condition at Baseline (more numerous inflammatory lesions). Lesion counts continued to drop at all evaluations over the duration of the study, indicating that further improvements may be expected with a duration of treatment exceeding nine weeks. Twice daily (BID) application of 2.5% Omiganan did not demonstrate substantial improvement in lesion reduction or the number of patients reaching Treatment Success compared to once daily application. Based on the results from this study, Cutanea has selected a once-daily dose of Omiganan 2.5% for further development for the treatment of papulopustular rosacea.

Dr. Guy Webster, Founding and Current President of the American Acne & Rosacea Society and Clinical Professor of Dermatology at Jefferson Medical College stated, "Topical Omiganan is a novel approach, actually the first in a new class of dermatologic drugs, for the treatment of rosacea. Initial results are promising and I look f
'/>"/>

SOURCE Cutanea Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Anthem Blue Cross patients ... have required them to obtain their medications by mail ... and Whatley Kallas LLC.  The lawsuit, ... that Blue Cross,s mandatory mail order program announced late ... and privacy. "This settlement brings to a ...
(Date:5/23/2013)... -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative ... that it has initiated dosing in a Phase I ... therapy for the treatment of HCV infection. This study will ... to assess both the safety and antiviral efficacy of ... the treatment of chronic HCV infections and is based ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... 2 Trials in Colorectal Cancer,and in Hormone-Refractory ... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Poniard ... oncology, today announced,promising results from an interim ... of picoplatin, a new generation platinum for,the ...
... Launches 1,000-Patient Lung Cancer Diversity Study, CHICAGO, June ... the leading cause of cancer death in,African-Americans, with ... deaths expected this year.(i) Equally devastating, lung,cancer is ... men and the,second leading cause of cancer death ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11
(Date:5/24/2013)... (PRWEB) May 25, 2013 myMEDholiday.com, a ... of healthcare providers in five important medical travel destinations ... International Patient Guide to ensure a safe and ... This 15-step manual offers tips on cost-savings, how ... plan your itinerary, and a wealth other essential advice. ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... 24, 2013 This week is National ... their efforts to provide the best emergency care and ... this week is also to educate the public that ... survival. Citizens are the first link, and a very ... bystander CPR after a cardiac arrest can triple a ...
(Date:5/24/2013)... for heart failure appear to have better odds of ... morning, a new study finds. Death rates and ... admitted in January, on Fridays and overnight, according to ... Saturday in Portugal at the annual meeting of the ... "The fact that patients admitted right before ...
(Date:5/24/2013)... Orlando, Florida (PRWEB) May 24, 2013 KC ... are the Title Sponsors for FreeRide836. Their oldest sons, Kyle ... Mark and Tracey Russell family and several professional kiteboarders. , ... this amazing project. "This has miraculously come together such that ... be able to participate." , 20 kite boarders will meet ...
Breaking Medicine News(10 mins):Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3
... widespread awareness being propagated by the Indian government many AIDS patients ... even possess the basic knowledge about AIDS.// ,Newly ... destiny dealt a cruel blow - she was infected with AIDS ... 13 years later, she has not only put up a tough ...
... few technological advancements have had the potential to revolutionize ... so on. The Internet has indeed made the world ... Internet, there has been a parallel increase in the ... Internet has of late become a playground that allows ...
... marriage, hurled at them, when they accidentally discover 'Gay' tendencies ... and the marriage appears to come to a grinding halt.// ... respiratory therapist in rural Minnesota, who in June of 2000 ... they spoke about it and wept over it, her husband ...
... or impotence can now be used in treating pulmonary ... pharmaceutical company, is marketing the drug under the brand ... approved for use in last November by the European ... as the pill, Viagra. The drug is already being ...
... Department of Pathology MLN Medical College in Allahabad recently ... pathological spectrum of oral cancer' and has uncovered some ... the tumor registry between 1990 to 2000. ... the department, 759 biopsies were of the oral cavity. ...
... obsessed with the perfect weight and figure so they follow ... phenomenon in view a comparison of several // popular diets ... study after one year, sticking with a diet—more than the ... ,Michael L. Dansinger, Ernst J. Schaefer, and Joi A. Gleason ...
Cached Medicine News:Health News:Misconceptions Put AIDS Patients In Tight-Spot 2Health News:Cyber Sex, No Longer A Fantasy Of The Mind 2Health News:Do not follow popular diets, stick to one that is best for you! 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: